CTXR
Citius Pharmaceuticals, Inc.1.1000
+0.0400+3.77%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
20.32MP/E (TTM)
-Basic EPS (TTM)
-4.87Dividend Yield
0%Recent Filings
8-K
LYMPHIR launches for CTCL
Citius Oncology launched LYMPHIR nationwide on December 1, 2025, targeting relapsed or refractory Stage I-III CTCL after prior therapy. The FDA-approved IL-2 fusion protein showed 36.2% ORR and 1.4-month median response time in its pivotal trial, entering a $400M+ U.S. market. LYMPHIR is now shipping to wholesalers. Capillary leak syndrome risks demand close monitoring.
8-K
LYMPHIR launch set Q4 2025
Citius Pharmaceuticals posted an updated October 2025 corporate presentation under Item 7.01, highlighting LYMPHIR's FDA approval for relapsed/refractory CTCL and Q4 2025 commercialization via spun-off majority-owned subsidiary Citius Oncology (CTOR). Mino-Lok's Phase 3 trial beat endpoints, extending catheter life beyond six weeks versus 33 days for controls. Halo-Lido Phase 2b showed symptom relief. Launch nears, but not filed.
8-K
Citius closes $6M offering
Citius Pharmaceuticals closed a $6.0 million registered direct offering on October 21, 2025, selling 1,460,000 shares and pre-funded warrants for 2,513,510 shares at $1.51, plus warrants for 3,973,510 shares exercisable at $1.40 through 2030. Net proceeds of $5.5 million will fund LYMPHIR's commercial launch, including milestones and regulatory costs, while supporting other product development and corporate needs. Yet dilution looms large for shareholders.
10-Q
Q3 FY2025 results
Citius Pharmaceuticals narrowed its Q3 FY2025 operating loss to $8.8M from $10.6M a year earlier, thanks to lower R&D spending on completed Mino-Lok trials and reduced stock-based comp, while G&A ticked up on LYMPHIR pre-launch efforts. For the nine months, the net loss widened to $31.0M from $28.3M, driven by higher commercialization costs and no offsetting gain from New Jersey NOL sales seen last year; operating loss improved slightly to $30.1M from $30.9M (derived). Cash burn eased to $14.7M from operations, bolstered by $16.5M in equity raises, leaving $6.1M on hand amid $27.2M negative working capital and looming $22.5M milestone to Dr. Reddy's plus $18.3M manufacturing commitments. Inventory swelled to $17.2M for LYMPHIR's Q4 launch. LYMPHIR's path looks solid post-FDA nod. Yet funding remains tight.
8-K
Citius narrows Q3 loss, funds LYMPHIR launch
Citius Pharmaceuticals reported a narrowed Q3 fiscal 2025 net loss of $9.2 million, down from $10.6 million a year earlier, as R&D expenses dropped to $1.6 million from $2.8 million while G&A held steady at $4.4 million. The company raised $12.5 million in financings during the quarter, plus $9 million more via Citius Oncology in July, bolstering cash to $6.1 million and funding LYMPHIR's Q4 2025 U.S. launch for cutaneous T-cell lymphoma. Final manufacturing and distribution pacts are locked in. Yet funding needs loom beyond September 2025.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
BLRX
BioLineRx Ltd.
3.01-0.17
CPRX
Catalyst Pharmaceuticals, Inc.
24.19+0.01
CRMD
CorMedix Inc.
11.44+0.11
CTOR
Citius Oncology, Inc.
1.07+0.02
CUE
Cue Biopharma, Inc.
0.41-0.05
LIMN
Liminatus Pharma, Inc.
0.78+0.02
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
TARS
Tarsus Pharmaceuticals, Inc.
78.28-2.20